Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin

American Surgeon

Volumn 66, Issue 6, 2000, Pages 561-568

  Loggie, Brian W ^a,b   Fleming, Ronald A ^a   Mcquellon, Richard P ^a   Russell, Gregory B ^a   Geisinger, Kim R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UTSW Moncrief Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOMYCIN C;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HYPERTHERMIC THERAPY; LEUKOPENIA; MALE; PERITONEUM CANCER; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; APPENDICEAL NEOPLASMS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEMALE; GASTROINTESTINAL NEOPLASMS; HEAT; HUMANS; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 0034098315     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Chu DZ, Lang NP, Thompson C, et al. Pertioneal carcinomatosis in nongynecologic malignancy: A prospective study of prognostic factors. Cancer 1989;63:364-7.
2. Yazdi GP, Miedema BW, Humphrey LJ. High mortality after abdominal operation in patients with large-volume malignant ascites. J Surg Oncol 1996;62:93-6.
3. Baines M, Oliver DJ, Carter RL. Medical management of intestinal obstruction in patients with advanced malignant disease. Lancet 1985;8462:990-3.
4. Stuart GC, Nation JG, Snider DD, Thunberg P. Intraperitoneal interferon in the management of malignant ascites. Cancer 1993;71:2027-30.
5. Bezwoda WR, Golombick T, Dansey R, Keeping J. Treatment of malignant ascites due to recurrent/refractory ovarian cancer: The use of interferon-alpha or interferon-alpha plus chemotherapy in vivo and in vitro. Eur J Cancer 1991;27:1423-9.
6. Rath U, Kaufmann M, Schmid H, et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur J Cancer 1991;27:121-5.
7. Kaufmann M, Schmid H, Raeth U, et al. Therapy of ascites with tumor necrosis factor in ovarian cancer (German). Geburtshilfe Frauenheilkd 1990;50:678-82.
8. Kirmani S, Lucas WE. A Phase II trial of cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma. J Clin Oncol 1991;9:649-57.
9. Howell SB, Zimm S, Markman M. Long term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987;5:1607-12.
10. Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985;12(3 Suppl 4):1-6.
11. Watanabe M, Tanaka R, Hondo H, Kuroki M. Effects of antineoplastic agents and hyperthermia on cytotoxicity toward chronically hypoxic glioma cells. Int J Hypertherm 1992;8:131-8.
12. Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC. Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res 1981;41:1096-9.
13. Wallner KE, Banda M, Li GC. Hyperthermic enhancement of cell killing by mitomycin C in mitomycin C-resistant Chinese hamster ovary cells. Cancer Res 1987;47:1308-12.
14. Alexander HR, Buell JF, Fraker DL. Rationale and clinical status of continuous hyperthermic peritoneal perfusion for the treatment of peritoneal carcinomatosis. Princ Prac Oncol Updates 1995;9:1.
15. Fujimoto S, Takahashi M, Kobayashi K, et al. Cytohistologic assessment of antitumor effects of intraperitoneal hyperthermic perfusion with mitomycin C for patients with gastric cancer with peritoneal metastases. Cancer 1992;70:2754-60.
16. Yonemura Y, Fujimura T, Fushida S, et al. Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg 1991;15:530-6.
17. Fujimoto S, Takahashi M, Kobayashi K, et al. Relation between clinical and histologic outcome of intraperitoneal hyperthermic perfusion for patients with gastric cancer and peritoneal metastasis. Oncology 1993;50:338-43.
18. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.
20. Sugarbaker PH, Zhu BW, Sese GB, Shmookler B. Peritoneal carcinomatosis from appendiceal cancer: Results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum 1993;36:323-9.
21. Sugarbaker PH, Schellinx MET, Chang D, et al. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 1996;20:585-92.
22. Schneebaum S, Arnold MW, Staubus A, et al. Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Ann Surg Oncol 1996;3:44-50.
23. Yonemura Y, Fujimura T, Nishimura G, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996;119:437-44.
24. Fujimoto S, Shrestha RD, Kokubun D, et al. Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. Ann Surg 1990;212: 592-6.
25. Fujimoto S, Takahashi M, Mutou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997;79:884-91.
26. Koga S, Hamazoe R, Maeta M, et al. Prophylactic therapy for peritoneal recurrence of gastric by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988;61:232-7.
27. Kaibara N, Hamazoe R, Iitsuka Y, et al. Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer. Hepatogastroenterology 1989;36:75-8.
28. Marincola FM, Schwartzentruber DJ. Malignant ascites. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principle and Practice of Oncology. Philadelphia: Lippincott-Raven, 1997, p 2598.
29. Sayag AC, Gilly FN, Carry PY, et al. Intraoperative chemohyperthermia in the management of digestive cancers. Oncology 1993;50:333-7.
30. Gilly FN, Carry PY, Brachet A, et al. Treatment of malignant peritoneal effusion in digestive and ovarian cancer. Med Oncol Tumor Pharmacol 1992;9:177-81.
31. Iitsuka Y, Kaneshima S, Tanida O, et al. Intraperitoneal free cancer cells and their viability in gastric cancer. Cancer 1979;44: 1476-80.
32. Lei S, Kini J, Kim K, Howard JM. Pancreatic cancer: Cytologic study of peritoneal washings. Arch Surg 1994;129:639-42.
33. Koga S, Kaibara N, Iitsuka Y, et al. Prognostic significance of intraperitoneal free cancer cells in gastric cancer patients. J Cancer Res Clin Oncol 1984;108:236-8.
34. Sugarbaker PH. Intraperitoneal chemotherapy for treatment and prevention of peritoneal carcinomatosis and sarcomatosis. Dis Colon Rectum 1994;37 (Suppl):S115.
35. Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 1993;113:631-6.
36. Fleming RA, Loggie BW, Russell GB, Rice MA. Systemic exposure of mitomycin C during intraperitoneal administration is correlated with hematologic toxicity and survival in patients with peritoneal carcinomatosis (Abstract). Proc Am Assoc Cancer Res 1998;39:599.
37. Dorr RT. New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C. Semin Oncol 1988;15 (Suppl 4):32.
38. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989; 16:327-36.
39. Harmon BV, Corder AM, Collings RJ, et al. Cell death induced in a murine mastocytoma by 42-47 degrees C heating in vitro: Evidence that the form of death changes from apoptosis to necrosis above a critical heat load. Int J Radiat Biol 1990;58: 845-58.
40. Harmon BV, Takano YS, Winterford CM, Gobe GC. The role of apoptosis in the response of cells and tumours to mild hyperthermia. Int J Radiat Biol 1991;59:489-501.
41. Yao K, Clayton M, O'Dwyer PJ. Interaction of heat and hypoxia in modulating transcription of DT-diaphorase in human colon adenocarcinoma cells. Cell Growth Differ 1994;5:125-31.
42. Fujimoto S, Shrestha RD, Kokubun M, et al. Clinical trial with surgery and intraperitoneal hyperthermic perfusion for peritoneal recurrence of gastrointestinal cancer. Cancer 1989;64: 154-60.
43. Chen MY, Chiles C, Loggie BW, Choplin RH, Perini MA, Fleming RA. Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. J Surg Oncol 1997;66:19-23.
44. McQuellon RP, Loggie BW, Russell GB, Fleming RA, Craven BS, Rambo TD, Sergeant RA. Health-related quality of life before and after surgically directed intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis (Abstract). Proc Am Soc Clin Oncol 1997;16:76a.